| pubmed-article:15708635 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15708635 | lifeskim:mentions | umls-concept:C0206580 | lld:lifeskim |
| pubmed-article:15708635 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:15708635 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:15708635 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:15708635 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15708635 | pubmed:dateCreated | 2005-2-14 | lld:pubmed |
| pubmed-article:15708635 | pubmed:abstractText | CpG-DNA has been described as a potent activator of the innate immune system, with potential to protect against infection caused by a range of pathogens in a non-specific manner. Here two classes of CpG-DNA (CpG-A and CpG-B) have been investigated for their abilities to protect mice from infection with an orthopoxvirus (vaccinia virus). Dosing with either CpG-A or B by the intraperitonal or intranasal route protected mice against a subsequent intranasal challenge with vaccinia virus. To our knowledge, this is the first time CpG-mediated protection has been demonstrated at the lung surface. The level of protection was greater when CpG-DNA was administered intranasally demonstrating a clear relationship between the route of CpG dosing and infection route. Treatment with CpG-B reduced viral titer in the lung by 10,000-fold at day 3 post-infection. The CC chemokines RANTES and MIP-1beta were elevated in the broncho-alveolar lavage from animals treated intranasally with CpG-B compared to untreated and intraperitoneally dosed controls, and it is possible that these chemokines play a role in the clearance of intranasally delivered vaccinia virus. | lld:pubmed |
| pubmed-article:15708635 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15708635 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15708635 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15708635 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15708635 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15708635 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15708635 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15708635 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15708635 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:15708635 | pubmed:issn | 0166-3542 | lld:pubmed |
| pubmed-article:15708635 | pubmed:author | pubmed-author:TitballRichar... | lld:pubmed |
| pubmed-article:15708635 | pubmed:author | pubmed-author:KriegArthur... | lld:pubmed |
| pubmed-article:15708635 | pubmed:author | pubmed-author:GreenMichaelM | lld:pubmed |
| pubmed-article:15708635 | pubmed:author | pubmed-author:GriffinKate... | lld:pubmed |
| pubmed-article:15708635 | pubmed:author | pubmed-author:ReesD G... | lld:pubmed |
| pubmed-article:15708635 | pubmed:author | pubmed-author:GatesAmanda... | lld:pubmed |
| pubmed-article:15708635 | pubmed:author | pubmed-author:EastaughLinL | lld:pubmed |
| pubmed-article:15708635 | pubmed:author | pubmed-author:LukaszewskiRo... | lld:pubmed |
| pubmed-article:15708635 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15708635 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:15708635 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15708635 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15708635 | pubmed:pagination | 87-95 | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:meshHeading | pubmed-meshheading:15708635... | lld:pubmed |
| pubmed-article:15708635 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15708635 | pubmed:articleTitle | CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. | lld:pubmed |
| pubmed-article:15708635 | pubmed:affiliation | Defence Science and Technology Laboratory (DSTL), Porton Down, Salisbury, Wiltshire SP4 0JQ, UK. crees1@dstl.gov.uk | lld:pubmed |
| pubmed-article:15708635 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15708635 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15708635 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15708635 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15708635 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15708635 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15708635 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15708635 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15708635 | lld:pubmed |
